Filing Flows › Kura Oncology (KURA) › Q3 2025
Kura Oncology (KURA) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 4, 2025
Kura Oncology (KURA) reported revenue of $20.8M for the third quarter 2025 (Q3 2025) and +36% from the quarter before. Operating margin was -385.5%, net loss $74.1M (357.2% of revenue).
Kura Oncology, Q3 2025: revenue $20.8M, operating margin -385.5%, net loss $74.1M, operating cash flow −$80.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.8M | +36% | — |
| Operating profit | −$80.0M | — | — |
| Net earnings | −$74.1M | — | — |
| Operating cash flow | −$80.6M | — | — |
What changed
Revenue was $20.8M in Q3 2025, up 36% from the previous quarter.
Operating costs exceeded revenue by $80.0M, an operating margin of -385.5%. The quarter ended with a net loss of $74.1M, wider than the previous quarter's $66.1M loss.
Operating cash flow was −$80.6M. Non-cash charges added back $164K of depreciation and $11.0M of share-based compensation. Working capital and other items used $17.6M. Capital expenditures of $2.6M exceeded it, leaving free cash flow of −$83.2M.
Questions
What was Kura Oncology's revenue in the third quarter 2025?
Kura Oncology (KURA) reported revenue of $20.8M for the third quarter 2025 (Q3 2025) and +36% from the quarter before.
Was Kura Oncology profitable in the third quarter 2025?
Operating loss was $80.0M (-385.5% of revenue) and net loss $74.1M.
Source: Kura Oncology 10-Q on SEC EDGAR.